These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33153146)

  • 21. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular Modeling Studies of
    Ghosh S; Keretsu S; Cho SJ
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
    Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
    Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of Conformational Control Inhibitors Switching off the Activated c-KIT and Targeting a Broad Range of Clinically Relevant c-KIT Mutants.
    Wu TS; Lin WH; Tsai HJ; Hsueh CC; Hsu T; Wang PC; Lin HY; Peng YH; Lu CT; Lee LC; Tu CH; Kung FC; Shiao HY; Yeh TK; Song JS; Chang JY; Su YC; Chen LT; Chen CT; Jiaang WT; Wu SY
    J Med Chem; 2019 Apr; 62(8):3940-3957. PubMed ID: 30968693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase.
    Li B; Wang A; Liu J; Qi Z; Liu X; Yu K; Wu H; Chen C; Hu C; Wang W; Wu J; Hu Z; Ye L; Zou F; Liu F; Wang B; Wang L; Ren T; Zhang S; Bai M; Zhang S; Liu J; Liu Q
    J Med Chem; 2016 Sep; 59(18):8456-72. PubMed ID: 27545040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New therapeutic agents in gastrointestinal stromal tumours.
    Falkenhorst J; Hamacher R; Bauer S
    Curr Opin Oncol; 2019 Jul; 31(4):322-328. PubMed ID: 31033566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
    Weisberg E; Choi HG; Ray A; Barrett R; Zhang J; Sim T; Zhou W; Seeliger M; Cameron M; Azam M; Fletcher JA; Debiec-Rychter M; Mayeda M; Moreno D; Kung AL; Janne PA; Khosravi-Far R; Melo JV; Manley PW; Adamia S; Wu C; Gray N; Griffin JD
    Blood; 2010 May; 115(21):4206-16. PubMed ID: 20299508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors].
    Xu J; Cao H
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):288-91. PubMed ID: 23536353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
    Schuetze SM; Bolejack V; Thomas DG; von Mehren M; Patel S; Samuels B; Choy E; D'Amato G; Staddon AP; Ganjoo KN; Chow WA; Rushing DA; Forscher CA; Priebat DA; Loeb DM; Chugh R; Okuno S; Reinke DK; Baker LH
    JAMA Oncol; 2018 Jun; 4(6):814-820. PubMed ID: 29710216
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
    Lasota J; Miettinen M
    Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BLU-285, DCC-2618 Show Activity against GIST.
    Cancer Discov; 2017 Feb; 7(2):121-122. PubMed ID: 28077435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insight into the structural features of pyrazolopyrimidine- and pyrazolopyridine-based B-Raf(V600E) kinase inhibitors by computational explorations.
    Li Y; Han C; Wang J; Yang Y; Zhang J; Zhang S; Yang L
    Chem Biol Drug Des; 2014 Jun; 83(6):643-55. PubMed ID: 24373283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of novel
    Elasbali AM; Al-Soud WA; Elfaki EM; Alanazi HH; Alharbi B; Alharethi SH; Anwer K; Mohammad T; Hassan MI
    J Biomol Struct Dyn; 2024 Jul; 42(11):5982-5994. PubMed ID: 37403288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design of Novel IRAK4 Inhibitors Using Molecular Docking, Dynamics Simulation and 3D-QSAR Studies.
    Bhujbal SP; He W; Hah JM
    Molecules; 2022 Sep; 27(19):. PubMed ID: 36234844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastrointestinal stromal tumors.
    Antonescu C
    Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.
    Serrano-Candelas E; Ainsua-Enrich E; Navinés-Ferrer A; Rodrigues P; García-Valverde A; Bazzocco S; Macaya I; Arribas J; Serrano C; Sayós J; Arango D; Martin M
    Mol Oncol; 2018 Aug; 12(8):1383-1397. PubMed ID: 29885053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy.
    Wardelmann E; Büttner R; Merkelbach-Bruse S; Schildhaus HU
    Virchows Arch; 2007 Oct; 451(4):743-9. PubMed ID: 17701051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
    Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J
    Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening.
    Chaudhari P; Bari S
    Mol Divers; 2016 Feb; 20(1):41-53. PubMed ID: 26416560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.